Results 241 to 250 of about 9,284,227 (272)
Some of the next articles are maybe not open access.
Ca 15-3 a Marker for the Megaloblastic Anaemia?.
Blood, 2005Abstract Ca 15-3 is a glycoprotein present in the cells of the mammary carcinoma and in some epithelial cells. Is a marker used for the monitoring of the breast and gastrointestinal carcinoma. The megaloblastic anaemia is an anaemia characterized by deficit of absorption of Vitamin B12 and is associated with gastritis atrophic and the ...
Vincenzo Mettivier +5 more
openaire +1 more source
The significance of determining CA 15-3 in the cytosol of breast cancer
Journal of Cancer Research and Clinical Oncology, 1992The identification of tumor markers in patients who had undergone operation for breast cancer provides important information in the follow-up in addition to evaluation by clinical and visual methods. The aim of our study was to determine the clinical prospective value of CA 15-3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in ...
K, Kosian +3 more
openaire +2 more sources
Human Chorionic Gonadotropin and CA 15-3 Producing Adenocarcinoma
Nuklearmedizin, 1998Summary50 years old man suffering from primary lung adenocarcinoma presented with high levels of both beta subunit human chorionic gonadotropin (βHCG) and cancer antigen 15-3 (CA 15-3) in the absence of elevated carcinoembrionic antigen (CEA), alfa fetoprotein (AFP) and carbohydrate antigen 19-9 (CA 19-9).
G, Uçkaya +3 more
openaire +2 more sources
Clinical Applications of CA 15–3
1992Circulating breast cancer associated tumor markers have several potential clinical uses. Although many circulating molecules have been investigated as putative breast cancer markers, only a few have been found to have sufficient sensitivity and specificity to be useful clinically. Of these, carcinoembryonic antigen (CEA) has been the most commonly used
Daniel F. Hayes +2 more
openaire +1 more source
CA 15-3 in patients with locoregional and metastatic breast carcinoma
Cancer, 1992The value of circulating CA 15-3 levels was assessed in 129 patients with recurrent breast carcinoma.Patients were divided into four subgroups, according to the following: Group A, locoregional recurrence alone; Group B, locoregional and subsequent systemic recurrence; Group C, combined locoregional and systemic recurrence; and Group D, differing sites
J G, Geraghty +4 more
openaire +2 more sources
CEA and CA 15‐3 in primary and recurrent breast cancer
World Journal of Surgery, 1990AbstractTo evaluate CA 15‐3, a new breast cancer associated antigen, and to compare it with carcinoembryonic antigen (CEA), all patients presenting with breast cancer had preoperative and serial (3‐monthly) postoperative levels measured. Of 124 patients with primary breast cancer, 23% had an elevated CA 15‐3 (>25 units/ml) while 11% had an elevated ...
P J, O'Dwyer +5 more
openaire +2 more sources
Informations Réactifs : CA 15-3
Immuno-analyse & Biologie Spécialisée, 2001Resume Cette rubrique est alimentee par les informations recueillies aupres de l'Agence francaise de securite sanitaire des produits de sante (direction de l'evaluation des dispositifs in vitro, departement diagnostic in vitro, unite enregistrement des reactifs) et des industriels.
openaire +1 more source
CA 15-3: Uses and limitation as a biomarker for breast cancer
Clinica Chimica Acta, 2010CA 15-3 which detects soluble forms of MUC-1 protein is the most widely used serum marker in patients with breast cancer. Its main use is for monitoring therapy in patients with metastatic disease. In monitoring therapy in this setting, CA 15-3 should not be used alone but measured in conjunction with diagnostic imaging, clinical history and physical ...
Michael J, Duffy +2 more
openaire +2 more sources
La Revue de medecine interne, 1995
The precise clinical value of CA 15-3 antigen has yet to be determined. With no role in screening for early breast cancer and, even if CA 15-3 seems to be correlated with bulky initial tumor burden, it appears to have no independent prognostic value. The clinical interest of CA 15-3 remains the early detection of the first recurrence.
E, Antoine, L, Kayitalire, M, Spielmann
openaire +1 more source
The precise clinical value of CA 15-3 antigen has yet to be determined. With no role in screening for early breast cancer and, even if CA 15-3 seems to be correlated with bulky initial tumor burden, it appears to have no independent prognostic value. The clinical interest of CA 15-3 remains the early detection of the first recurrence.
E, Antoine, L, Kayitalire, M, Spielmann
openaire +1 more source
Tumor Marker CA 15-3 in Hematological Malignancies.
Blood, 2006Abstract Introduction: CA 15-3 is a glycoprotein expressed in several adenocarcinomas, especially of the breast. It is used to detect recurrent or metastatic disease. Elevated levels can also be found in adenocarcinomas of the ovary, lung, pancreas, and colon, and are also related to benign breast or ovarian disease, endometriosis ...
Charalambos Andreadis +7 more
openaire +1 more source